Last reviewed · How we verify
Ponticelli Regimen
The Ponticelli Regimen is an immunosuppressive treatment protocol that combines corticosteroids and cyclophosphamide to suppress immune-mediated kidney damage.
The Ponticelli Regimen is an immunosuppressive treatment protocol that combines corticosteroids and cyclophosphamide to suppress immune-mediated kidney damage. Used for Membranous nephropathy with nephrotic syndrome.
At a glance
| Generic name | Ponticelli Regimen |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | Immunosuppressive combination regimen |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Immunology |
| Phase | FDA-approved |
Mechanism of action
This regimen alternates monthly cycles of intravenous methylprednisolone and cyclophosphamide with oral corticosteroids to induce remission in membranous nephropathy. The cyclophosphamide provides cytotoxic immunosuppression while corticosteroids reduce inflammation, together targeting the autoimmune attack on the glomerular basement membrane.
Approved indications
- Membranous nephropathy with nephrotic syndrome
Common side effects
- Infection
- Bone marrow suppression
- Gastrointestinal toxicity
- Hemorrhagic cystitis
- Hyperglycemia
Key clinical trials
- Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (NA)
- Multitarget Therapy for Idiopathic Membranous Nephropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ponticelli Regimen CI brief — competitive landscape report
- Ponticelli Regimen updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI